Pantop

# Pantop ## Overview - **Classification**: Proton Pump Inhibitor (PPI) - **Mechanism**: Irreversibly blocks the H+/K+ ATPase (proton pump) in gastric parietal cells, significantly reducing gastric acid secretion. ## Primary Indications 1. **Erosive Esophagitis (GERD)** - Healing and maintenance 2. **Zollinger-Ellison Syndrome (ZES)** - Management of pathological hypersecretory conditions 3. **H. pylori Eradication** - As part of a multi-drug regimen 4. **Duodenal Ulcers** - Short-term treatment ## Adult Dosing ### Standard Dosing **Erosive Esophagitis (GERD)** - **Dose**: **40 mg** - **Frequency**: Once daily - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: Up to 8 weeks for healing; maintenance **20-40 mg** PO daily. **Zollinger-Ellison Syndrome & Pathological Hypersecretory Conditions** - **Dose**: Initial **40 mg** - **Frequency**: Twice daily (BID) - **Route**: PO or IV - **Maximum Dose**: Up to **240 mg/day** in divided doses (higher doses for ZES may be needed). **H. pylori Eradication** (as part of combination therapy) - **Dose**: **40 mg** - **Frequency**: Twice daily (BID) - **Route**: PO - **Duration**: Typically 7-14 days with antibiotics. ### Dose Adjustments - **Renal Impairment**: No dose adjustment is needed. - **Hepatic Impairment**: Max dose **40 mg** once daily for severe impairment (Child-Pugh C). - **Elderly Patients**: No specific adjustment needed; consider risk for long-term adverse effects. ## Pediatric Dosing ### Neonates (0-28 days) - **Use**: **Not routinely recommended** due to limited safety and efficacy data. - **Special Notes**: Use only if potential benefits outweigh risks, under specialist supervision. ### Infants (1-12 months) - **Indication**: Erosive Esophagitis (limited data) - **Dose**: **0.6-1.2 mg/kg** - **Frequency**: Once daily - **Maximum**: **40 mg** once daily - **Special Notes**: Consider liquid formulations or suspension for ease of administration. ### Children (1-12 years) - **Indication**: Erosive Esophagitis - **Dose**: - **15 to <23 kg**: **20 mg** - **≥23 kg**: **40 mg** - **Frequency**: Once daily - **Route**: PO - **Duration**: Up to 8 weeks. ### Adolescents (13-18 years) - **Indication**: Erosive Esophagitis - **Dose**: **40 mg** - **Frequency**: Once daily - **Route**: PO - **Maximum**: **40 mg** daily for GERD. - **Special Notes**: Dosing similar to adults. ## Safety Information ### Contraindications - **Absolute**: Known hypersensitivity to pantoprazole or substituted benzimidazoles. ### Common Adverse Effects - **Very Common (>10%)**: Headache - **Common (1-10%)**: Diarrhea, nausea, abdominal pain, flatulence, dizziness, rash. - **Serious but Rare**: *Clostridioides difficile* infection (CDI), interstitial nephritis, bone fractures (long-term), hypomagnesemia (long-term), vitamin B12 deficiency (long-term). ### Key Drug Interactions - **Clopidogrel**: Decreased antiplatelet effect due to CYP2C19 inhibition. Avoid co-administration if possible. - **Antiretrovirals (e.g., Atazanavir, Nelfinavir)**: Reduced absorption due to increased gastric pH. Avoid concomitant use. - **Methotrexate**: Increased methotrexate levels/toxicity. Monitor closely, consider temporary PPI discontinuation. - **Drugs requiring acidic pH (e.g., Ketoconazole, Iron salts)**: Decreased absorption. Consider alternative agents or timing. ## Monitoring & Follow-up - **Before Treatment**: Assess baseline symptoms and indication. - **During Treatment**: Symptom resolution, monitor for adverse effects. - **During Long-Term Treatment (>1 year)**: - **Electrolytes**: Periodically monitor serum magnesium. - **Renal Function**: Monitor for signs of acute interstitial nephritis. - **Bone Density**: Consider screening for fracture risk in high-risk patients. - **Vitamin B12**: Assess for deficiency with prolonged use. - **Clinical Signs**: Watch for persistent diarrhea (CDI), muscle cramps/weakness (hypomagnesemia), or unexplained fractures. ## Clinical Pearls - 💡 **Timing**: Take **30-60 minutes before a meal**, preferably in the morning. - 💡 **Administration**: Do **not crush, chew, or split** delayed-release tablets. - 💡 **Long-term Use**: Re-evaluate the continued need for PPIs periodically to use the lowest effective dose for the shortest duration. - 💡 **IV Formulations**: IV pantoprazole is for patients who cannot take oral therapy. Switch to oral as soon as possible. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.